Xspray Pharma invites to a conference call following receipt of CRL for Dasynoc
Xspray Pharma invites investors, analysts and media to a conference call following the company’s receipt of a Complete Response Letter, CRL, from the U.S. Food and Drug Administration, FDA, in relation to the company’s New Drug Application, NDA for Dasynoc. The receipt of the CRL was announced in a press release earlier today, 19 August 2026.
Date: Thursday, 20 August 2026
Time: 09:00 CEST
Speaker: Blake Leitch, CEO of Xspray Pharma
Language: English
The conference call will be hosted by Xspray Pharma’s CEO Blake Leitch, who will comment on the content of the CRL, the main remaining questions from the FDA and the company’s view of the next steps in the process. The presentation will be held in English and will conclude with a Q&A session.
If you wish to participate via webcast, please use the following link: https://xspray.events.inderes.com/press-conference-aug-2026
Via the webcast, you are able to ask written questions.
If you wish to ask questions verbally via the teleconference, please register using the following link: https://events.inderes.com/xspray/press-conference-aug-2026/dial-in
After registration, you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
For further information, please contact:
Jacob Nyberg, IRO
Xspray Pharma AB (publ)
Tel: + 46 (0) 70 767 08 83
E-mail: ir@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development utilizing its innovative, patent protected HyNap™ technology platform to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology market segment, often with high drug prices. The company’s goal is to become the market leader in improved PKI’s for cancer treatment. Xspray Pharma’s lead drug candidate, Dasynoc® and Nilopki® (an optimized version of Tasigna®) are currently undergoing FDA review. Dasynoc is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose due to a better solubility profile. Its compatibility with proton pump inhibitors (PPIs), which are often co-prescribed to patients with CML and ALL, is a significant advantage. Xspray Pharma is building a robust product portfolio, including Nilopki and XS008-axitinib (an optimized version of Inlyta®) and XS025-cabozantinib (an optimized version of Cabometyx®).
The Xspray Pharma AB-share is trading at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com.